更多开发者作品
The Lancet Oncology
| 1. | [Clinical Picture] When leukaemia masquerades: the hidden syphilis diagnosis | Meryl Musicante, Julianna Martel Harrell, Shelby Kubicki, Jonathan L Curry, Anisha B Patel | |
| 2. | [Editorial] Curbing the climb in cancer incidence | The Lancet Oncology | |
| 3. | [Comment] No prime time yet for checkpoint inhibitors in localised head and neck squamous cell carcinoma | Jens Voortman | |
| 4. | [Articles] Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer (TOPAZ-1): patient-reported outcomes from a randomised, double-blind, placebo-controlled, phase 3 trial | Howard A Burris, Takuji Okusaka, Arndt Vogel, Myung Ah Lee, Hidenori Takahashi, Valeriy Breder, Jean-Frédéric Blanc, Junhe Li, Melinda Bachini, Magdalena Żotkiewicz, Jayne Abraham, Nikunj Patel, Julie Wang, Muzammil Ali, Nana Rokutanda, Gordon Cohen, Do-Youn Oh | |
| 5. | [Perspectives] The fate of sotorasib: a regulatory failure potentially harming patients | Sruthi Ranganathan, Vinay Prasad, Timothée Olivier | |
| 6. | [Review] Considerations for using potential surrogate endpoints in cancer screening trials | Alexis B Webb, Christine D Berg, Philip E Castle, David Crosby, Ruth Etzioni, Larry G Kessler, Usha Menon, Mahesh Parmar, Robert J C Steele, Peter D Sasieni | |
| 7. | [Corrections] Correction to Lancet Oncol 2023; 24: 1094–108 | | |
| 8. | [Policy Review] International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma | Paula Rodriguez-Otero, Saad Usmani, Adam D Cohen, Niels W C J van de Donk, Xavier Leleu, Jaime Gállego Pérez-Larraya, Salomon Manier, Ajay K Nooka, Maria Victoria Mateos, Hermann Einsele, Monique Minnema, Michele Cavo, Benjamin A Derman, Noemi Puig, Francesca Gay, P Joy Ho, Wee-Joo Chng, Efstathios Kastritis, Gösta Gahrton, Katja Weisel, Chandramouli Nagarajan, Fredik Schjesvold, Joseph Mikhael, Luciano Costa, Noopur S Raje, Elena Zamagni, Roman Hájek, Niels Weinhold, Kwee Yong, Jing Christine Ye, Surbhi Sidhana, Giampaolo Merlini, Tom Martin, Yi Lin, Ajai Chari, Rakesh Popat, Jonathan L Kaufman, International Myeloma Working Group | |
| 9. | [Correspondence] Alternative approaches to risk–benefit balancing in immunotherapy | Yusuf Ilhan, Yakup Ergun | |
| 10. | [Comment] Cancer and incarceration: a call for action | Ilana B Richman, Cary P Gross, Emily A Wang | |
| 11. | [Correspondence] Olanzapine for chemotherapy-induced nausea and vomiting control | Seiji Tsuruta, Kunihito Matsuguma, Naruaki Kawasaki, Ayaka Ishikawa, Hiroto Ishiki | |
| 12. | [Correspondence] Olanzapine for chemotherapy-induced nausea and vomiting control – Authors’ reply | Jyoti Bajpai, Akash Pawar, Venkatesh Kapu, Kumar Prabhash | |
| 13. | [Correspondence] Olanzapine for chemotherapy-induced nausea and vomiting control | Vinod Sharma, Apoorva Dadheech, Atul Yadav, Jitendra Kumar Pehalajani, Naresh Somani | |
| 14. | [Correspondence] Olanzapine for chemotherapy-induced nausea and vomiting control | Venkatraman Radhakrishnan, Ramakrishnan Ayloor Seshadri, Sreekumaran Nair | |
| 15. | [Personal View] Protecting Caribbean patients diagnosed with cancer from compounding disasters | Ana Patricia Ortiz, C James Hospedales, Pablo A Méndez-Lázaro, William M Hamilton, LaShae D Rolle, J Marshall Shepherd, Zelde Espinel, Hiram A Gay, Leticia M Nogueira, James M Shultz | |
| 16. | [Articles] Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): patient-reported outcomes from a randomised, open-label, multicentre, phase 3 trial | Tanja Fehm, Francesco Cottone, Kyle Dunton, Fabrice André, Ian Krop, Yeon Hee Park, Michelino De Laurentiis, Yasuo Miyoshi, Anne Armstrong, Manuel Ruiz Borrego, Rinat Yerushalmi, Francois P Duhoux, Toshimi Takano, Wenjing Lu, Anton Egorov, Sung-Bae Kim | |
| 17. | [Correspondence] Evaluating cancer care in low-income and middle-income countries | Vrindha Pari, Bharath Kumar Tirupakuzhi Vijayaraghavan, Bruce M Biccard, Madiha Hashmi | |
| 18. | [Articles] Cancer incidence, treatment, and survival in the prison population compared with the general population in England: a population-based, matched cohort study | Margreet Lüchtenborg, Jennie Huynh, Jo Armes, Emma Plugge, Rachael M Hunter, Renske Visser, Rachel M Taylor, Elizabeth A Davies | |
| 19. | [Policy Review] Delphi consensus on stereotactic ablative radiotherapy for oligometastatic and oligoprogressive renal cell carcinoma—a European Society for Radiotherapy and Oncology study endorsed by the European Association of Urology | Giulia Marvaso, Barbara Alicja Jereczek-Fossa, Mattia Zaffaroni, Maria Giulia Vincini, Giulia Corrao, Nicolaus Andratschke, Ehsan H Balagamwala, Jens Bedke, Oliver Blanck, Umberto Capitanio, Rohann J M Correa, Gert De Meerleer, Ciro Franzese, Aurora Gaeta, Sara Gandini, Cristina Garibaldi, Peter C Gerszten, Silke Gillessen, William R Grubb, Matthias Guckenberger, Raquibul Hannan, Pavan M Jhaveri, Mirjana Josipovic, Linda G W Kerkmeijer, Eric J Lehrer, Magnus Lindskog, Alexander V Louie, Quynh-Nhu Nguyen, Piet Ost, David A Palma, Giuseppe Procopio, Maddalena Rossi, Michael Staehler, Alison C Tree, Yat Man Tsang, Nicholas Van As, Nicholas G Zaorsky, Thomas Zilli, David Pasquier, Shankar Siva | |
| 20. | [News] Proposed bill to support assisted dying in France | Sharmila Devi | |
| 21. | [News] US EPA sets historic new restrictions on toxic PFAS in drinking water | Bryant Furlow | |
| 22. | [News] Cancer Workforce Fund launched to address oncology workforce crisis | Emma Wilkinson | |
| 23. | [News] Study bolsters concerns about US FDA accelerated drug approvals | Bryant Furlow | |
| 24. | [Articles] Changes in hospital mortality in patients with cancer during the COVID-19 pandemic (ISARIC-CCP-UK): a prospective, multicentre cohort study | Lance Turtle, Sarah Elliot, Thomas M Drake, Mathew Thorpe, Emma G Khoury, William Greenhalf, Hayley E Hardwick, Gary Leeming, Andy Law, Wilna Oosthuyzen, Riinu Pius, Catherine A Shaw, J Kenneth Baillie, Peter J M Openshaw, Annemarie B Docherty, Malcolm G Semple, Ewen M Harrison, Carlo Palmieri, ISARIC4C Investigators | |
| 25. | [News] Nigeria revitalises national cancer response with new initiatives | Paul Adepoju | |
| 26. | [Comment] Combining enzalutamide and [177Lu]Lu-PSMA-617 in metastatic castration-resistant prostate cancer | Nadine Houédé, Kevin Hebert | |
| 27. | [Articles] [177Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial | Louise Emmett, Shalini Subramaniam, Megan Crumbaker, Andrew Nguyen, Anthony M Joshua, Andrew Weickhardt, Sze-Ting Lee, Siobhan Ng, Roslyn J Francis, Jeffrey C Goh, David A Pattison, Thean Hsiang Tan, Ian D Kirkwood, Craig Gedye, Natalie K Rutherford, Shahneen Sandhu, Aravind Ravi Kumar, David Pook, Shakher Ramdave, David P Nadebaum, Mark Voskoboynik, Andrew D Redfern, William Macdonald, Laurence Krieger, Geoff Schembri, Wei Chua, Peter Lin, Lisa Horvath, Patricia Bastick, Patrick Butler, Alison Yan Zhang, Sonia Yip, Hayley Thomas, Ailsa Langford, Michael S Hofman, Margaret McJannett, Andrew James Martin, Martin R Stockler, Ian D Davis, ENZA-p Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group | |
| 28. | [News] Advisory Group recommendations on priorities for the IARC Monographs | Amy Berrington de González, Scott A Masten, Parveen Bhatti, Renée Turzanski Fortner, Susan Peters, Tiina Santonen, Marianna G Yakubovskaya, Robert Barouki, Silvia B M Barros, Dinesh Barupal, Laura E Beane Freeman, Gloria M Calaf, Joakim Dillner, Karima El Rhazi, Lin Fritschi, Shoji Fukushima, Lode Godderis, Manolis Kogevinas, Dirk W Lachenmeier, Daniele Mandrioli, Mazvita M Muchengeti, Richard T Niemeier, Jane J Pappas, Jingbo Pi, Mark P Purdue, Elio Riboli, Teresa Rodríguez, Vivi Schlünssen, Lamia Benbrahim-Tallaa, Aline de Conti, Caterina Facchin, Elisa Pasqual, Roland Wedekind, Ayat Ahmadi, Shirisha Chittiboyina, Zdenko Herceg, Shalini Kulasingam, Béatrice Lauby-Secretan, Richard MacLehose, Moez Sanaa, Joachim Schüz, Eero Suonio, Jiri Zavadil, Heidi Mattock, Federica Madia, Mary K Schubauer-Berigan | |
| 29. | [Articles] Cabozantinib monotherapy for advanced adrenocortical carcinoma: a single-arm, phase 2 trial | Matthew T Campbell, Vania Balderrama-Brondani, Camilo Jimenez, Gina Tamsen, Leonardo P Marcal, Jeena Varghese, Amishi Y Shah, James P Long, Miao Zhang, Joshua Ochieng, Cara Haymaker, Mouhammed Amir Habra | |
| 30. | [Comment] Mitotane: a friend or a foe before cabozantinib treatment in adrenocortical cancer? | Margaret E Wierman | |
| 31. | [Articles] Cabozantinib in patients with unresectable and progressive metastatic phaeochromocytoma or paraganglioma (the Natalie Trial): a single-arm, phase 2 trial | Camilo Jimenez, Mouhammed Amir Habra, Matthew T Campbell, Gina Tamsen, Damaris Cruz-Goldberg, James Long, Roland Bassett, Robert Dantzer, Vania Balderrama-Brondani, Jeena Varghese, Yang Lu | |
| 32. | [Articles] Nivolumab with or without ipilimumab in patients with recurrent or metastatic cervical cancer (CheckMate 358): a phase 1–2, open-label, multicohort trial | Ana Oaknin, Kathleen Moore, Tim Meyer, José López-Picazo González, Lot A Devriese, Asim Amin, Christopher D Lao, Valentina Boni, William H Sharfman, Jong Chul Park, Makoto Tahara, Suzanne L Topalian, Manuel Magallanes, Alejandro Molina Alavez, Tariq Aziz Khan, Catherine Copigneaux, Michelle Lee, Charlie Garnett-Benson, Xuya Wang, R Wendel Naumann | |
| 33. | [Articles] MRI-guided optimisation of neoadjuvant chemotherapy duration in stage II–III HER2-positive breast cancer (TRAIN-3): a multicentre, single-arm, phase 2 study | Anna van der Voort, Fleur M Louis, Mette S van Ramshorst, Rob Kessels, Ingrid A Mandjes, Inge Kemper, Mariette J Agterof, Wim A van der Steeg, Joan B Heijns, Marlies L van Bekkum, Ester J Siemerink, Philomeen M Kuijer, Astrid Scholten, Jelle Wesseling, Marie-Jeanne T F D Vrancken Peeters, Ritse M Mann, Gabe S Sonke, Dutch Breast Cancer Research Group | |
| 34. | [News] Expansion of radiotherapy access in Ethiopia | Manjulika Das | |
| 35. | [Articles] Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial | Jean-Pascal Machiels, Yungan Tao, Lisa Licitra, Barbara Burtness, Makoto Tahara, Danny Rischin, Gustavo Alves, Iane Pinto Figueiredo Lima, Brett G M Hughes, Yoann Pointreau, Sercan Aksoy, Simon Laban, Richard Greil, Martin Burian, Marcin Hetnał, Jean-Pierre Delord, Ricard Mesía, Miren Taberna, John N Waldron, Christian Simon, Vincent Grégoire, Kevin J Harrington, Ramona F Swaby, Yayan Zhang, Burak Gumuscu, Behzad Bidadi, Lillian L Siu, KEYNOTE-412 Investigators | |
| 36. | [News] Environmental pollution and cancer risk in La Oraya, Peru | Manjulika Das | |
| 37. | [News] UK tobacco and vapes bill one step closer | Priya Venkatesan | |
| 38. | [News] SSO 2024 | Allison Landman | |
| 39. | [Articles] Clinical and biological landscape of constitutional mismatch-repair deficiency syndrome: an International Replication Repair Deficiency Consortium cohort study | Ayse Bahar Ercan, Melyssa Aronson, Nicholas R Fernandez, Yuan Chang, Adrian Levine, Zhihui Amy Liu, Logine Negm, Melissa Edwards, Vanessa Bianchi, Lucie Stengs, Jiil Chung, Abeer Al-Battashi, Agnes Reschke, Alex Lion, Alia Ahmad, Alvaro Lassaletta, Alyssa T Reddy, Amir F Al-Darraji, Amish C Shah, An Van Damme, Anne Bendel, Aqeela Rashid, Ashley S Margol, Bethany L Kelly, Bojana Pencheva, Brandie Heald, Brianna Lemieux-Anglin, Bruce Crooks, Carl Koschmann, Catherine Gilpin, Christopher C Porter, David Gass, David Samuel, David S Ziegler, Deborah T Blumenthal, Dennis John Kuo, Dima Hamideh, Donald Basel, Dong-Anh Khuong-Quang, Duncan Stearns, Enrico Opocher, Fernando Carceller, Hagit Baris Feldman, Helen Toledano, Ira Winer, Isabelle Scheers, Ivana Fedorakova, Jack M Su, Jaime Vengoechea, Jaroslav Sterba, Jeffrey Knipstein, Jordan R Hansford, Julieta Rita Gonzales-Santos, Kanika Bhatia, Kevin J Bielamowicz, Khurram Minhas, Kim E Nichols, Kristina A Cole, Lynette Penney, Magnus Aasved Hjort, Magnus Sabel, Maria Joao Gil-da-Costa, Matthew J Murray, Matthew Miller, Maude L Blundell, Maura Massimino, Maysa Al-Hussaini, Mazin F Al-Jadiry, Melanie A Comito, Michael Osborn, Michael P Link, Michal Zapotocky, Mithra Ghalibafian, Najma Shaheen, Naureen Mushtaq, Nicolas Waespe, Nobuko Hijiya, Noemi Fuentes-Bolanos, Olfat Ahmad, Omar Chamdine, Paromita Roy, Pavel N Pichurin, Per Nyman, Rachel Pearlman, Rebecca C Auer, Reghu K Sukumaran, Rejin Kebudi, Rina Dvir, Robert Raphael, Ronit Elhasid, Rose B McGee, Rose Chami, Ryan Noss, Ryuma Tanaka, Salmo Raskin, Santanu Sen, Scott Lindhorst, Sebastien Perreault, Shani Caspi, Shazia Riaz, Shlomi Constantini, Sophie Albert, Stanley Chaleff, Stefan Bielack, Stefano Chiaravalli, Stuart Louis Cramer, Sumita Roy, Suzanne Cahn, Suzanne Penna, Syed Ahmer Hamid, Tariq Ghafoor, Uzma Imam, Valerie Larouche, Vanan Magimairajan Issai, William D Foulkes, Yi Yen Lee, Paul C Nathan, Yosef E Maruvka, Mary-Louise C Greer, Carol Durno, Adam Shlien, Birgit Ertl-Wagner, Anita Villani, David Malkin, Cynthia Hawkins, Eric Bouffet, Anirban Das, Uri Tabori | |
| 40. | [News] 1 in 9 USA cancer diagnoses missed during 2020 COVID-19 pandemic | Tony Kirby | |
| 41. | [News] EPA ruling to ban chrysotile asbestos | Talha Burki | |
| 42. | [News] Arsenic contamination and cancer risk in Bangladesh | Manjulika Das | |
更新于 34 分钟前
近期历史最近 100 条记录
| 2024-04-30 | [Clinical Picture] When leukaemia masquerades: the hidden syphilis diagnosis | Meryl Musicante, Julianna Martel Harrell, Shelby Kubicki, Jonathan L Curry, Anisha B Patel | |
| 2024-04-30 | [Editorial] Curbing the climb in cancer incidence | The Lancet Oncology | |
| 2024-04-30 | [Comment] No prime time yet for checkpoint inhibitors in localised head and neck squamous cell carcinoma | Jens Voortman | |
| 2024-04-30 | [Articles] Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer (TOPAZ-1): patient-reported outcomes from a randomised, double-blind, placebo-controlled, phase 3 trial | Howard A Burris, Takuji Okusaka, Arndt Vogel, Myung Ah Lee, Hidenori Takahashi, Valeriy Breder, Jean-Frédéric Blanc, Junhe Li, Melinda Bachini, Magdalena Żotkiewicz, Jayne Abraham, Nikunj Patel, Julie Wang, Muzammil Ali, Nana Rokutanda, Gordon Cohen, Do-Y | |
| 2024-04-30 | [Perspectives] The fate of sotorasib: a regulatory failure potentially harming patients | Sruthi Ranganathan, Vinay Prasad, Timothée Olivier | |
| 2024-04-30 | [Review] Considerations for using potential surrogate endpoints in cancer screening trials | Alexis B Webb, Christine D Berg, Philip E Castle, David Crosby, Ruth Etzioni, Larry G Kessler, Usha Menon, Mahesh Parmar, Robert J C Steele, Peter D Sasieni | |
| 2024-04-30 | [Corrections] Correction to Lancet Oncol 2023; 24: 1094–108 | | |
| 2024-04-30 | [Policy Review] International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma | Paula Rodriguez-Otero, Saad Usmani, Adam D Cohen, Niels W C J van de Donk, Xavier Leleu, Jaime Gállego Pérez-Larraya, Salomon Manier, Ajay K Nooka, Maria Victoria Mateos, Hermann Einsele, Monique Minnema, Michele Cavo, Benjamin A Derman, Noemi Puig, Franc | |
| 2024-04-30 | [Correspondence] Alternative approaches to risk–benefit balancing in immunotherapy | Yusuf Ilhan, Yakup Ergun | |
| 2024-04-30 | [Comment] Cancer and incarceration: a call for action | Ilana B Richman, Cary P Gross, Emily A Wang | |
| 2024-04-30 | [Correspondence] Olanzapine for chemotherapy-induced nausea and vomiting control | Seiji Tsuruta, Kunihito Matsuguma, Naruaki Kawasaki, Ayaka Ishikawa, Hiroto Ishiki | |
| 2024-04-30 | [Correspondence] Olanzapine for chemotherapy-induced nausea and vomiting control – Authors’ reply | Jyoti Bajpai, Akash Pawar, Venkatesh Kapu, Kumar Prabhash | |
| 2024-04-30 | [Correspondence] Olanzapine for chemotherapy-induced nausea and vomiting control | Vinod Sharma, Apoorva Dadheech, Atul Yadav, Jitendra Kumar Pehalajani, Naresh Somani | |
| 2024-04-30 | [Correspondence] Olanzapine for chemotherapy-induced nausea and vomiting control | Venkatraman Radhakrishnan, Ramakrishnan Ayloor Seshadri, Sreekumaran Nair | |
| 2024-04-30 | [Personal View] Protecting Caribbean patients diagnosed with cancer from compounding disasters | Ana Patricia Ortiz, C James Hospedales, Pablo A Méndez-Lázaro, William M Hamilton, LaShae D Rolle, J Marshall Shepherd, Zelde Espinel, Hiram A Gay, Leticia M Nogueira, James M Shultz | |
| 2024-04-30 | [Articles] Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): patient-reported outcomes from a randomised, open-label, multicentre, phase 3 trial | Tanja Fehm, Francesco Cottone, Kyle Dunton, Fabrice André, Ian Krop, Yeon Hee Park, Michelino De Laurentiis, Yasuo Miyoshi, Anne Armstrong, Manuel Ruiz Borrego, Rinat Yerushalmi, Francois P Duhoux, Toshimi Takano, Wenjing Lu, Anton Egorov, Sung-Bae Kim | |
| 2024-04-30 | [Correspondence] Evaluating cancer care in low-income and middle-income countries | Vrindha Pari, Bharath Kumar Tirupakuzhi Vijayaraghavan, Bruce M Biccard, Madiha Hashmi | |
| 2024-04-30 | [Articles] Cancer incidence, treatment, and survival in the prison population compared with the general population in England: a population-based, matched cohort study | Margreet Lüchtenborg, Jennie Huynh, Jo Armes, Emma Plugge, Rachael M Hunter, Renske Visser, Rachel M Taylor, Elizabeth A Davies | |
| 2024-04-30 | [Policy Review] Delphi consensus on stereotactic ablative radiotherapy for oligometastatic and oligoprogressive renal cell carcinoma—a European Society for Radiotherapy and Oncology study endorsed by the European Association of Urology | Giulia Marvaso, Barbara Alicja Jereczek-Fossa, Mattia Zaffaroni, Maria Giulia Vincini, Giulia Corrao, Nicolaus Andratschke, Ehsan H Balagamwala, Jens Bedke, Oliver Blanck, Umberto Capitanio, Rohann J M Correa, Gert De Meerleer, Ciro Franzese, Aurora Gaeta | |
| 2024-04-30 | [News] US EPA sets historic new restrictions on toxic PFAS in drinking water | Bryant Furlow | |
| 2024-04-30 | [News] Proposed bill to support assisted dying in France | Sharmila Devi | |
| 2024-04-30 | [News] Study bolsters concerns about US FDA accelerated drug approvals | Bryant Furlow | |
| 2024-04-30 | [News] Cancer Workforce Fund launched to address oncology workforce crisis | Emma Wilkinson | |
| 2024-04-30 | [Articles] Changes in hospital mortality in patients with cancer during the COVID-19 pandemic (ISARIC-CCP-UK): a prospective, multicentre cohort study | Lance Turtle, Sarah Elliot, Thomas M Drake, Mathew Thorpe, Emma G Khoury, William Greenhalf, Hayley E Hardwick, Gary Leeming, Andy Law, Wilna Oosthuyzen, Riinu Pius, Catherine A Shaw, J Kenneth Baillie, Peter J M Openshaw, Annemarie B Docherty, Malcolm G | |
| 2024-04-30 | [Articles] [177Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial | Louise Emmett, Shalini Subramaniam, Megan Crumbaker, Andrew Nguyen, Anthony M Joshua, Andrew Weickhardt, Sze-Ting Lee, Siobhan Ng, Roslyn J Francis, Jeffrey C Goh, David A Pattison, Thean Hsiang Tan, Ian D Kirkwood, Craig Gedye, Natalie K Rutherford, Shah | |
| 2024-04-30 | [Comment] Combining enzalutamide and [177Lu]Lu-PSMA-617 in metastatic castration-resistant prostate cancer | Nadine Houédé, Kevin Hebert | |
| 2024-04-30 | [News] Nigeria revitalises national cancer response with new initiatives | Paul Adepoju | |
| 2024-04-30 | [News] Advisory Group recommendations on priorities for the IARC Monographs | Amy Berrington de González, Scott A Masten, Parveen Bhatti, Renée Turzanski Fortner, Susan Peters, Tiina Santonen, Marianna G Yakubovskaya, Robert Barouki, Silvia B M Barros, Dinesh Barupal, Laura E Beane Freeman, Gloria M Calaf, Joakim Dillner, Karima El | |
| 2024-04-30 | [Articles] Cabozantinib monotherapy for advanced adrenocortical carcinoma: a single-arm, phase 2 trial | Matthew T Campbell, Vania Balderrama-Brondani, Camilo Jimenez, Gina Tamsen, Leonardo P Marcal, Jeena Varghese, Amishi Y Shah, James P Long, Miao Zhang, Joshua Ochieng, Cara Haymaker, Mouhammed Amir Habra | |
| 2024-04-30 | [Comment] Mitotane: a friend or a foe before cabozantinib treatment in adrenocortical cancer? | Margaret E Wierman | |
| 2024-04-30 | [Articles] Nivolumab with or without ipilimumab in patients with recurrent or metastatic cervical cancer (CheckMate 358): a phase 1–2, open-label, multicohort trial | Ana Oaknin, Kathleen Moore, Tim Meyer, José López-Picazo González, Lot A Devriese, Asim Amin, Christopher D Lao, Valentina Boni, William H Sharfman, Jong Chul Park, Makoto Tahara, Suzanne L Topalian, Manuel Magallanes, Alejandro Molina Alavez, Tariq Aziz | |
| 2024-04-30 | [Articles] Cabozantinib in patients with unresectable and progressive metastatic phaeochromocytoma or paraganglioma (the Natalie Trial): a single-arm, phase 2 trial | Camilo Jimenez, Mouhammed Amir Habra, Matthew T Campbell, Gina Tamsen, Damaris Cruz-Goldberg, James Long, Roland Bassett, Robert Dantzer, Vania Balderrama-Brondani, Jeena Varghese, Yang Lu | |
| 2024-04-30 | [Articles] MRI-guided optimisation of neoadjuvant chemotherapy duration in stage II–III HER2-positive breast cancer (TRAIN-3): a multicentre, single-arm, phase 2 study | Anna van der Voort, Fleur M Louis, Mette S van Ramshorst, Rob Kessels, Ingrid A Mandjes, Inge Kemper, Mariette J Agterof, Wim A van der Steeg, Joan B Heijns, Marlies L van Bekkum, Ester J Siemerink, Philomeen M Kuijer, Astrid Scholten, Jelle Wesseling, Ma | |
| 2024-04-30 | [News] Expansion of radiotherapy access in Ethiopia | Manjulika Das | |
| 2024-04-30 | [Articles] Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial | Jean-Pascal Machiels, Yungan Tao, Lisa Licitra, Barbara Burtness, Makoto Tahara, Danny Rischin, Gustavo Alves, Iane Pinto Figueiredo Lima, Brett G M Hughes, Yoann Pointreau, Sercan Aksoy, Simon Laban, Richard Greil, Martin Burian, Marcin Hetnał, Jean-Pier | |
| 2024-04-30 | [News] Environmental pollution and cancer risk in La Oraya, Peru | Manjulika Das | |
| 2024-04-30 | [News] UK tobacco and vapes bill one step closer | Priya Venkatesan | |
| 2024-04-30 | [News] SSO 2024 | Allison Landman | |
| 2024-04-30 | [Articles] Clinical and biological landscape of constitutional mismatch-repair deficiency syndrome: an International Replication Repair Deficiency Consortium cohort study | Ayse Bahar Ercan, Melyssa Aronson, Nicholas R Fernandez, Yuan Chang, Adrian Levine, Zhihui Amy Liu, Logine Negm, Melissa Edwards, Vanessa Bianchi, Lucie Stengs, Jiil Chung, Abeer Al-Battashi, Agnes Reschke, Alex Lion, Alia Ahmad, Alvaro Lassaletta, Alyssa | |
| 2024-04-30 | [News] 1 in 9 USA cancer diagnoses missed during 2020 COVID-19 pandemic | Tony Kirby | |
| 2024-04-30 | [News] EPA ruling to ban chrysotile asbestos | Talha Burki | |
| 2024-04-30 | [News] Arsenic contamination and cancer risk in Bangladesh | Manjulika Das | |
| 2024-03-26 | [Comment] A new era of risk prediction for patients with high-risk melanoma | Roger Olofsson Bagge, Tina J Hieken | |
| 2024-03-26 | [Comment] Combining chemotherapy and immunotherapy for advanced anal cancer: are we ready? | Erika Martinelli, Davide Ciardiello | |
| 2024-03-26 | [Comment] Venetoclax in patients with relapsed or refractory chronic lymphocytic leukaemia | Lin Yang, Versha Banerji | |
| 2024-03-26 | [Clinical Picture] Gastric signet-ring cell adenocarcinoma masquerading as sarcoidosis | Samy Belkaïd, Laura Crumbach, Axel de Bernardi, Sophie Darnis, Margot Bouquerel, Anne Neuhart, Souad Assaad, Mona Amini-Adle | |
| 2024-03-26 | [Editorial] Intellectual and developmental disabilities—an under-recognised driver of cancer mortality | The Lancet Oncology | |
| 2024-03-26 | [Policy Review] Cancer control collaborations between China and African countries | Twalib Ngoma, Isaac Adewole, Victoria Ainsworth, David Chin, Jennifer Chin, Ahmed Elzawawy, Adedayo Joseph, Abba Mallum, Ntokozo Ndlovu, Mamsau Ngoma, Aishat Oladipo, William Swanson, Wilfred Ngwa | |
| 2024-03-26 | [Policy Review] The socioeconomic impact of cancer on patients and their relatives: Organisation of European Cancer Institutes task force consensus recommendations on conceptual framework, taxonomy, and research directions | Michael Schlander, Wim van Harten, Valesca P Retèl, Phu Duy Pham, Julie M Vancoppenolle, Jasper Ubels, Olaya Seoane López, Camila Quirland, Felipe Maza, Eline Aas, Bernd Crusius, Agustín Escobedo, Nora Franzen, Jeanette Fuentes-Cid, Diego Hernandez, Karla | |
| 2024-03-26 | [Corrections] Correction to Lancet Oncol 2024; 25: 317–25 | | |
| 2024-03-26 | [Comment] The cost and value of cancer medicines in Ontario, Canada | Christopher J Longo | |
| 2024-03-26 | [Articles] Development and validation of a novel model to predict recurrence-free survival and melanoma-specific survival after sentinel lymph node biopsy in patients with melanoma: an international, retrospective, multicentre analysis | Robert C Stassen, Carolien C H M Maas, Astrid A M van der Veldt, Serigne N Lo, Robyn P M Saw, Alexander H R Varey, Richard A Scolyer, Georgina V Long, John F Thompson, Piotr Rutkowski, Ulrich Keilholz, Alexander C J van Akkooi, Cornelis Verhoef, David van | |
| 2024-03-26 | [Articles] LOAd703, an oncolytic virus-based immunostimulatory gene therapy, combined with chemotherapy for unresectable or metastatic pancreatic cancer (LOKON001): results from arm 1 of a non-randomised, single-centre, phase 1/2 study | Benjamin L Musher, Eric K Rowinsky, Brandon G Smaglo, Wasif Abidi, Mohamed Othman, Kalpesh Patel, Salmaan Jawaid, James Jing, Amanda Brisco, Ann M Leen, Mengfen Wu, Linda C Sandin, Jessica Wenthe, Emma Eriksson, Gustav J Ullenhag, Bambi Grilley, Justyna L | |
| 2024-03-26 | [Review] Optimal targeting of PI3K-AKT and mTOR in advanced oestrogen receptor-positive breast cancer | Iseult M Browne, Fabrice André, Sarat Chandarlapaty, Lisa A Carey, Nicholas C Turner | |
| 2024-03-26 | [Articles] Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-Lung01): primary results of the HER2-overexpressing cohorts from a single-arm, phase 2 trial | Egbert F Smit, Enriqueta Felip, Dipesh Uprety, Misako Nagasaka, Kazuhiko Nakagawa, Luis Paz-Ares Rodríguez, Jose M Pacheco, Bob T Li, David Planchard, Christina Baik, Yasushi Goto, Haruyasu Murakami, Andreas Saltos, Kaline Pereira, Ayumi Taguchi, Yingkai | |
| 2024-03-26 | [Articles] Gedatolisib in combination with palbociclib and endocrine therapy in women with hormone receptor-positive, HER2-negative advanced breast cancer: results from the dose expansion groups of an open-label, phase 1b study | Rachel M Layman, Hyo S Han, Hope S Rugo, Erica M Stringer-Reasor, Jennifer M Specht, E Claire Dees, Peter Kabos, Samuel Suzuki, Sarah C Mutka, Brian F Sullivan, Igor Gorbatchevsky, Robert Wesolowski | |
| 2024-03-26 | [Corrections] Correction to Lancet Oncol 2023; 24: 1399–410 | | |
| 2024-03-26 | [Articles] Cost and value of cancer medicines in a single-payer public health system in Ontario, Canada: a cross-sectional study | Joseph C Del Paggio, Rohini Naipaul, Scott Gavura, Rebecca E Mercer, Rachel Koven, Bishal Gyawali, Brooke E Wilson, Christopher M Booth | |
| 2024-03-26 | [Articles] Atezolizumab plus modified docetaxel, cisplatin, and fluorouracil as first-line treatment for advanced anal cancer (SCARCE C17-02 PRODIGE 60): a randomised, non-comparative, phase 2 study | Stefano Kim, Francois Ghiringhelli, Christelle de la Fouchardière, Ludovic Evesque, Denis Smith, Nicolas Badet, Emmanuelle Samalin, Daniel Lopez-Trabada Ataz, Aurelie Parzy, Jérôme Desramé, Nabil Baba Hamed, Bruno Buecher, David Tougeron, Olivier Bouché, | |
| 2024-03-26 | [News] Massive US cybersecurity breach highlights perils of health-care consolidation | Bryant Furlow | |
| 2024-03-26 | [Articles] Activity of venetoclax in patients with relapsed or refractory chronic lymphocytic leukaemia: analysis of the VENICE-1 multicentre, open-label, single-arm, phase 3b trial | Arnon P Kater, Önder Arslan, Fatih Demirkan, Yair Herishanu, Burhan Ferhanoglu, Marcos Gonzalez Diaz, Brian Leber, Marco Montillo, Panayiotis Panayiotidis, Davide Rossi, Alan Skarbnik, Adrian Tempescul, Mehmet Turgut, Clemens H Mellink, Anne-Marie F van d | |
| 2024-03-26 | [News] Non-communicable diseases in humanitarian settings | Talha Burki | |
| 2024-03-26 | [Perspectives] Innovation in gynaecological cancer: highlighting global disparities | Maria Kyrgiou, Sarah Bowden, Lynette Denny, Anna Fagotti, Nadim R Abu-Rustum, Pedro T Ramirez, Denis Querleu | |
| 2024-03-26 | [News] Alabama Supreme Court's “extrauterine children” decision alarms oncologists and fertility experts | Bryant Furlow | |
| 2024-03-26 | [Articles] Correlations of response rate and progression-free survival with overall survival in immunotherapy trials for metastatic non-small-cell lung cancer: an FDA pooled analysis | Bernardo Haddock Lobo Goulart, Sirisha L Mushti, Somak Chatterjee, Erin Larkins, Pallavi S Mishra-Kalyani, Richard Pazdur, Paul G Kluetz, Harpreet Singh | |
| 2024-03-26 | [News] Indonesia and the Philippines take steps to control cancer | Manjulika Das | |
| 2024-03-26 | [Articles] 68Ga-RM2 PET–MRI versus MRI alone for evaluation of patients with biochemical recurrence of prostate cancer: a single-centre, single-arm, phase 2/3 imaging trial | Heying Duan, Farshad Moradi, Guido A Davidzon, Tie Liang, Hong Song, Andreas M Loening, Shreyas Vasanawala, Sandy Srinivas, James D Brooks, Steven Hancock, Andrei Iagaru | |
| 2024-03-26 | [Comment] Towards world-class radiotherapy in the UK: time for transformation | Katie Wakeham, Tim Cooper, Carl Rowbottom, Anthony J Chalmers, Katie Spencer, Pat Price, Sarah Quinlan | |
| 2024-03-26 | [News] South Africa combats gaps in cancer data | Manjulika Das | |
匿名用户只展示最新 100 条榜单历史，更多历史数据请登录后查看，支持时光机按天筛选
Sponsors
